Condition: ALS (Amyotrophic Lateral Sclerosis) · FTD · Neuropathic · Sponsor: Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Diagnosis of ALS/FTD disease spectrum is challenging because it largely relies on clinical symptoms. Identifying novel biomarkers is essential for a paradigm shift towards a more precise biological-based diagnosis. To achieve this aim, having access to proper specimens and analytical methods is crucial. Our team of experts in neurology, biology, chemistry, physics, and AI will explore ALS/FTD from novel perspectives using transcriptomics, proteomics, genomics and other innovative approaches to analyzing easily accessible tissues. The seed amplification assay (SAA) will be also exploited to detect pathological TDP-43. This project aims to create disease fingerprints useful for patient stratification and monitoring of disease progression, and to evaluate the therapeutic efficacy in clinical trials, thus overcoming the limits of clinical interpretation. Discovering new biomarkers and cellular pathways will improve the diagnosis and treatment of these devastating diseases.
This description comes directly from the study's public registry record.
Fabio Moda, phd · 0223942770 · fabio.moda@istituto-besta.it
Arianna Ciullini, phd · 0223942249 · arianna.ciullini@istituto-besta.it
Always discuss trial participation with your own doctor first.
| Fondazione IRCCS Istituto Neurologico Carlo Besta | Milan, Italy | Recruiting |
| Università degli Studi di Napoli "Federico II" | Naples, Italy | Not Yet Recruiting |
| Azienda Ospedaliero Universitaria di Sassari | Sassari, Italy | Not Yet Recruiting |
| Consorzio Interuniversitario Risonanze Magnetiche Metallo Proteine (CIRMMP) | Sesto Fiorentino, Italy | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06856850